№ files_lp_3_process_9_38814
File format: docx Character count: 20150 File size: 58 KB
Year: [Insert year]
Region / city: [Insert region/city]
Subject: Medical treatment request
Document type: Authorization request letter
Institution: [Insert institution name]
Author: [Physician’s name]
Target audience: Medical/Pharmacy Director
Effective period: [Insert effective period]
Approval date: [Insert approval date]
Date of modifications: [Insert modification date]
Diagnosis: [Insert diagnosis]
Treatment: ERLEADA® (apalutamide)
Clinical trial: TITAN trial
Clinical guidelines reference: NCCN Guidelines®, AUA/SUO Guidelines
Patient history: [Insert patient history]
Risk of disease progression: [Insert risk]
Adverse reactions: Rash, hot flush, hypertension, arthralgia, pruritus
Publication reference: Journal of Clinical Oncology
Study data source: Precision Point Specialty (PPS) Analytics, Komodo Research Database
Study design: Retrospective, longitudinal, head-to-head analysis
Outcome: Overall survival at 24 months
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Request for Authorization for ERLEADA® (apalutamide) Treatment
Note: Year
Topic: Oncology
Document Type: Medical Treatment Authorization Request
Target Audience: Medical/Pharmacy Director
Clinicopathological and Demographics Data of Non-Metastatic Rectal Cancer Cohort by Treatment
Year: 2026
Study Type: Supplementary Table
Cohort Size: 76 patients
Treatment Groups: CRT, I+CRT, Unfront surgery
Parameters Measured: Age, Gender, Tumor Stage, EMVI, CRM, Lateral Lymph Nodes, CEA, CA19.9, NPS score, Histology, MMR status, CDX2 expression, HER2/Neu expression, CD3-CD8 TILs density, PD-L1 expression, Perineural invasion, Vascular invasion, pEMVI, pCRM
Data Source: Clinical records and histopathological analysis
Statistical Significance: p-values provided for each parameter
Topics: castration-sensitive ERLEADA non-metastatic